Autoantibody Reduction Therapy for Idiopathic Pulmonary Fibrosis
(STRIVE II Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This Phase IIb trial will compare effectiveness and safety of a multi-component autoantibody reduction therapy (AART), consisting of therapeutic plasma exchange (TPE), rituximab, and intravenous immunoglobulin (IVIg) for treatment of patients with progressive idiopathic pulmonary fibrosis (IPF).
Who Is on the Research Team?
Steven R Duncan, MD
Principal Investigator
University of Alabama at Birmingham
Are You a Good Fit for This Trial?
This trial is for adults with progressive idiopathic pulmonary fibrosis (IPF), a lung disease that gets worse over time. Participants should not have other major health problems or conditions that could interfere with the study.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Intravenous immunoglobulin
- Rituximab
- Therapeutic Plasma Exchange
Trial Overview
The study compares a combination therapy—plasma exchange, rituximab, and intravenous immunoglobulin—to standard treatment in people with worsening IPF to see if it helps slow down the disease.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Patients will be treated with combination of five (5) therapeutic plasma exchanges, followed by one dose of rituximab and then followed with four infusions of intravenous immunoglobulin (IVIg)
Patients will continue treatment(s) with optimized approved medications for idiopathic pulmonary fibrosis (IPF)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alabama at Birmingham
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.